within Pharmacolibrary.Drugs.C_CardiovascularSystem.C08D_SelectiveCalciumChannelBlockersWithDirectCardiac.C08DA02_Gallopamil;

model Gallopamil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.24,
    Cl = 1.9999999999999998e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0026,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.015000000000000001,
    Tlag = 10.200000000000001,
    Vdp = 0.0022,
    k12 = 2.3611111111111114e-05,
    k21 = 2.3611111111111114e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Gallopamil</td></tr><tr><td>ATC code:</td><td>C08DA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1200</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Gallopamil is a calcium channel blocker of the phenylalkylamine class, chemically related to verapamil. It was previously used for the treatment of angina pectoris and certain cardiac arrhythmias. However, it is not widely approved nor commonly used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Parameters estimated for adult healthy volunteers; no recent or original clinical PK studies directly cited in literature, parameters based on older references and secondary review sources.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C08DA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Gallopamil;
